All In Biotech

Free tool

FAERS Monitor: Azor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022100 or its brand name (Azor, Amlodipine Besylate, Olmesartan Medoxomil). Reports on generic versions are filed under their own applications.

Reports

2,511

Serious

1,462

58% of reports

Hospitalization

880

Death reported

91

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • sprue-like enteropathy327
  • gastrooesophageal reflux disease210
  • diarrhoea183
  • dizziness180
  • acute kidney injury170
  • weight decreased166
  • drug ineffective147
  • nausea138
  • haemorrhoids133
  • chronic kidney disease126
  • constipation116
  • fatigue111
  • headache98
  • asthenia95
  • flushing93

Reports by year received

View as table
YearReports
20072
200836
2009101
2010164
2011176
2012205
2013117
2014113
2015379
2016333
2017239
2018287
2019134
202072
202142
202221
202322
202422
202527
202619

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,648 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sprue-like enteropathySignal327595.1535.7180,570
haemorrhoidsSignal13357.548.77,283
gastrooesophageal reflux diseaseSignal21021.919.24,174
chronic kidney diseaseSignal12613.911.71,500
acute kidney injurySignal1709.38.11,261
flushingSignal937.76.3535
weight decreasedSignal1665.04.3531
constipationSignal1164.53.7311
dizzinessSignal1803.02.6248
diarrhoeaSignal1832.42.1149
astheniaSignal952.11.756
nausea1381.51.220
headache981.31.17
fatigue1111.21.03
drug ineffective1470.90.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.